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Toll-like receptors (TLRs) are a member of the innate immune system. TLRs detect invading pathogens through the pathogen-
associatedmolecularpatterns (PAMPs)recognition andplay anessentialrole inthe hostdefense. TLRs canalsosensea large num-
ber of endogenous molecules with the damage-associatedmolecular patterns (DAMPs) that are produced under various injurious
conditions. Animal studies of the last decade have demonstrated that TLR signaling contributes to the pathogenesis of the critical
cardiac conditions, where myocardial inﬂammation plays a prominent role, such as ischemic myocardial injury, myocarditis, and
septic cardiomyopathy. This paper reviews the animal data on (1) TLRs, TLR ligands, and the signal transduction system and (2)
the important role of TLR signalingin these critical cardiac conditions.
1.Introduction
Innate immune system represents the ﬁrst line of defense
against foreign pathogens. Toll-like receptors (TLRs) belong
to the family of pattern recognition receptors (PRRs). PRRs
recognize the conserved motifs in pathogens termed patho-
gen-associated molecular patterns (PAMPs) and trigger
innate immune response [1, 2]. In addition to participating
in the host defense against infectious pathogens, accumulat-
ing evidence suggests that TLRs also play an essential role in
tissue inﬂammationand contribute to “noninfectious” tissue
damage such as cardiac ischemia/reperfusion (I/R) injury,
postischemic remodeling, and atherosclerosis [3–6]. Thus,
understanding TLR signaling and their role in cardiovascu-
lar diseases may help to identify potential targets for inter-
vention and have important clinical implications. This paper
reviews TLR signaling and its critical roles in several inﬂam-
matory cardiac conditions: I/R injury, viral and autoimmune
myocarditis, and septic cardiomyopathy.
2.Toll-LikeReceptors
Toll means “amazing” and “fantastic” in German. In 1985,
Anderson and colleagues coined it for a protein critical for
early embryonic developmentof Drosophila [7, 8]. A decade
later, Lemaitre et al. found that this protein was also essential
to the host innate immunity against fungal infection in adult
ﬂies [9]. Subsequently, Medzhitov and colleagues identiﬁed
a mammalian homologue of the Drosophila Toll protein in
human and termed it “Toll-like receptor” [10]. Stimulation
of TLR signaling leads to the activation of transcription fac-
torssuch asNF-κB,oneofthemost important proinﬂamma-
tory transcription factors. To date, 11 human and 13 mouse
TLRs have been cloned. TLR1-TLR9 are conserved in both
human and mouse, and all of them are functional to recog-
nize diverseligands[2].However,mouseTLR10hasnofunc-
tion due to a retrovirus insertion, whereas human TLR10
m a yf u n c t i o na saT L R 2c o a c t i v a t o r[ 2, 11]. Finally, TLR11,
TLR12, and TLR13 are present in mouse but lost in human
[2].
TLRs are type I single-spanning membrane glycoprote-
ins with a leucine-rich repeat of extracellular domain, which
mediates ligand recognition, and an intracellular TIR do-
main, which recruits adaptors and activates downstream sig-
naling. According to the ligands and the subcellular loca-
tion, TLRs can be divided into two subgroups (Figure 1).
TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11 are located2 International Journal of Inﬂammation
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Figure 1: TLR signaling pathways. Upon respective ligands binding, TLRs form homo- or heterodimers and recruit one or more adaptor
proteins, namely, MyD88, MAL/TIRAP, TRIF, or TRAM, to the cytoplasmic domains of the receptors through homophilic interactions
between Toll/IL-1 receptor (TIR) domains present in each receptor and each adaptor. All TLRs with exception of TLR3 use the common
MyD88-dependent pathway. TIRAP acts as a bridge to recruit MyD88 to TLR2 and TLR4 signaling,whereas TRIF is used in TLR3 signaling
and, in association with TRAM, in TLR4 signaling. In MyD88-dependent pathway, MyD88 associates with IRAK4, IRAK1, and/or IRAK2.
IRAK4 in turn phosphorylates IRAK1 and/or IRAK2 and promotes their association with TRAF6, which serves as a platform to recruit and
activate the kinaseTAK1. Activated TAK1 activates the IKK complex, composed of IKKα,I K K β,a n dN E M O( I K K γ) ,w h i c hi nt u r nc a t a l y z e s
phosphorylation and subsequent degradation of IκB. IκB degradation lets NF-κB( i.e., p50/p65) free to translocate from the cytoplasma to
the nucleus, where it activates multiple gene expression. The transcription factor IRF7 is activated as the downstream signaling molecule of
TLR 7, 8, and 9. It is directly phosphorylated by IRAK1 and then translocates into the nucleus to induce the expression of type I IFN and
IFN-inducible genes. In the Trif-dependent pathway,Trif interacts with TRAF3 to activate TBK1 and IKKi, resulting in the dimerization and
activation of IRF3, which then translocates into the nucleus activating the transcription of type I IFN and IFN-inducible genes.
primarily on the cell surface and recognize mainly microbial
membrane componentssuch as lipids,lipoproteins, andpro-
teins. On the other hand, TLR3, TLR7, TLR8, and TLR9 re-
side on the membranes of intracellular compartments, such
as endosomes, lysosomes, endolysosomes, and endoplasmic
reticulum, and are responsible for the recognition of micro-
bial nucleic acids [2, 12].
2.1. TLR Ligands: PAMPs versus DAMPs. As summarized in
Table 1, TLRs consist of a family of receptors that speciﬁcally
bind to a wide range of pathogens including bacteria, fungi,
parasites, and viruses through “PAMPs” recognition [1, 2].
Accumulatingevidencehas indicatedthatTLRcanalso actas
a stress sensor in response to noninfectious tissue injury and
recognize a variety of endogenous stress molecules through
“DAMPs” recognition [13].
PAMPs. TLR4 was ﬁrst identiﬁed as the receptor for LPS, a
component of outer membrane of Gram-negative bacteria
[34, 35]. Its extracellular domain forms a complex with MD-
2 and serves as the main LPS-binding site [55]. Additional
proteins including LPS-binding protein and CD14 are also
involved in modulating LPS binding [56, 57]. TLR2 is the
most diverse TLR that recognizes a large number of PAMPs,
such as lipopeptides from diverse bacteria [14], peptidogly-
can [16, 17] and lipoteichoic acid [17]f r o mG r a m - p o s i t i v e
bacteria, LPS from certain Gram-negative bacteria [21], li-
poarabinomannan from mycobacteria [23, 24], zymosanInternational Journal of Inﬂammation 3
Table 1: TLR ligands: PAMPs versus DAMPs.
TLRs PAMPs Pathogens Ref. DAMPs Ref.
TLR2
Lipopeptides Bacteria [14]H S P 6 0 [15]
Peptidoglycan Gram+ bacteria [16, 17]H S P 7 0 [18, 19]
Lipoteichoic acid Gram+ bacteria [17] Gp96 [20]
LPS Leptospira
interrogans [21]H M G B 1 [22]
Lipoarabinomannan Mycobacteria [23, 24]b i o g l y c a n [25]
Zymosan Fungi [26]v e r s i c a n [27]
Glycosylphosphatidylinositol
anchors Trypanosoma [28] Hyaluronan
fragments
[29]
Hemagglutinin protein Measles virus [30]
TLR3
Double-stranded RNA
virus
[31] mRNA [32]
Poly(I:C) [31]
Smallinterfering RNAs [33]
TLR4 LPS Gram− bacteria [34, 35]
HSP60, HSP70,
HSP72, HSP22,
gp96
[15, 18–20, 36–39]
HMGB1 [22]
ﬁbronectin,
biglycan,
tenascin-C, and
versican
[25, 40, 41]
Hyaluronan, lower
molecular weight
HA, and heparin
sulfate
[42–44]
TLR5 ﬂagellin Bacteria ﬂagella [45]
TLR7
Single-stranded RNA [46]
Imidazoquinoline compounds virus [47] ssRNA [48]
Guanine analogs [49]
TLR8 Single-stranded RNA virus [50] ssRNA [48]
TLR9 Unmethylated CpG DNA motif Bacteria, virus [51] Chromatin-IgG
complex
[52]
TLR11 Proﬁlin-likemolecule Toxoplasma
gondii [53]
Uropathogenic
bacteria [54]
from fungi [26], glycosylphosphatidylinositol anchors from
Trypanosoma cruzi [28], and hemagglutinin protein from
measles virus [30]. It usually forms heterodimers with TLR1
or TLR6. In general, TLR1/2 recognizes triacylated lipopep-
tides [58], whereas TLR2/6 heterodimer recognizes diacylat-
edlipopeptides[59].TLR5recognizesﬂagellinfrom bacterial
ﬂagella [45], and TLR11 recognizes proﬁlin-like molecule
from the protozoan parasite Toxoplasma gondii [53]a n d4 International Journal of Inﬂammation
responsetouropathogenicbacteria[54].TLR3sensesdsRNA
[31], synthetic analog of dsRNA, such as poly(I:C) [31],
and certain small interfering RNAs [33]. It initiates antiviral
immune responses through the expression of type I IFN
and other inﬂammatory cytokines. TLR7 [46]a n dT L R 8
[50] sense ssRNA from RNAviruses, imidazoquinoline com-
pounds such as imiquimod and resiquimod (R-848) [47]
and guanine analogs [49]. TLR9 senses unmethylated dinu-
cleotides CpG DNA motifs, which are commonly present in
bacteria and viruses but lacking in mammalian cells [51].
DAMPs. These endogenous ligands are ECM fragments or
intracellular moleculesproducedeitherthrough release from
preformed precursor or by de novo synthesis in response to
tissueinjury.DAMP-activatedTLRsignalingreportedlyplays
an important role in the pathogenesis of many inﬂammatory
and autoimmune diseases. This topic is well reviewed by
Piccinini and Midwood [13].
HSP60wastheﬁrstendogenousmoleculelinkedtoTLRs.
Ohashi and colleagues found that similar to LPS, HSP60-
induced TNFα expression and nitric oxide production were
blockedin bone marrow-derived macrophages isolated from
TLR4-deﬁcient mice (C3H/HeJ strain) [36]. Since then, an
increasing list of endogenous molecules has been identiﬁed
to function as TLR ligands [2, 11, 13], includingintracellular
molecules released to extracellular environment after tissue
injury, such as HSPs including HSP60 [15], HSP70 [18, 19,
37], HSP72 [38], HSP22 [39]a n dg p 9 6[ 20], and HMGB1
[22]. Others are ECM molecule such as ﬁbronectin [40],
biglycan [25], tenascin-C [41], versican [27], and fragments
of ECM including oligosaccharides of hyaluronan [42],
lower molecular weight hyaluronan [29, 43], and heparan
sulfate [44]. In addition, chromatin-DNA and ribonucleo-
protein complexes released from injured cells can activate
intracellular TLRs. For example, mRNA exposure induces
NF-κB activation and IL-8 production in stable TLR3-
expressed HEK293cells. Meanwhile, TLR3speciﬁc-antibody
suppresses the activation of dendritic cells after stimulation
with in vitro transcribed RNA or endogenous RNA released
from necrotic cells [32]. In systemic lupus erythematosus,
plasmacytoid dendritic cells could be activated to secrete
type I IFN by RNA sequences through TLR7 and TLR8 [48].
Moreover, the ability to activate rheumatoid factor B cells in
response to IgG2a-chromatin immune complexes was abol-
ished in MyD88−/− mice, and the autoimmune complexes-
inducedactivationwasblockedbyvariousinhibitorsofTLR9
signaling [52].
2.2. TLR Signaling Pathways. As illustrated in Figure 1, upon
activation, TLRs form dimers and initiate the downstream
intracellular signaling. Heterodimerization occurs between
TLR2 and TLR1 or TLR6 and between TLR4 and MD-2,
whereas the other TLRs form homodimers. Ligand-induced
homo-hetero dimerization of TLRs triggers the cytoplasmic
signaling domains of the receptor to dimerize. The resulting
TIR-TIR complexes trigger speciﬁc biological responses by
initiating downstream signaling through a set of speciﬁc
adaptors. So far, 5 adaptors have been identiﬁed [60]. They
areMyD88,TIRAP,Trif,TRAM,andSARM[61].TLRsinter-
act with their respective adaptors via their TIR domain and
the homologous domain present in these adaptors. Depend-
ing on the adaptors recruited, TLRs signaling can be divided
into two distinct pathways: MyD88-dependent and Trif-de-
pendent pathways. Mal acts as a bridge adaptor to help
MyD88 recruiting to TLR2 and TLR4, whereas TRAM func-
tions as a sorting protein that recruits Trif to TLR4 [2, 61].
MyD88-Dependent Pathway. MyD88-dependent pathway is
activated by all TLRs with exception of TLR3. MyD88 sig-
naling leads to inﬂammatory cytokine production by acti-
vating the transcription factor NF-κBa n dM A P K s .M y D 8 8
recruits IL-1 receptor-associated kinases (IRAKs), such as
IRAK1,IRAK2,IRAK4,andIRAK-M.IRAK4isactivated ini-
tially and followed by the activation of IRAK1 and IRAK2,
leading to an interaction with TRAF6 [2]. The IRAK1-
TRAF6 complex then activates TAK1 through a process in-
volving cytosol translocation of TAK1 and two regulatory
components TAK-binding protein 2 (TAB2) and TAB3 and
theubiquitinationofTRAF6.ActivatedTAK1then phospho-
rylates IKKβ, leading to phosphorylation and degradation of
I-κB, which releases NF-κB and results in the nuclear trans-
location and DNA binding of NF-κB[ 2].
Trif-Dependent Pathway. Trif-dependent pathway is utilized
by TLR3 and TLR4. It induces type I IFN and inﬂammatory
cytokines through the activation of the transcription factor
interferon regulatory factor 3 (IRF3) and NF-κB. Trif asso-
ciateswith TRAF3andTRAF6.TRAF3links asignaling com-
plex involving the noncanonical IKKs, TRAF family mem-
ber-associated NF-κB activator (TANK) binding kinase-1
(TBK1) and IKKi, which catalyze phosphorylation of IRF3
and induce its nuclear translocation and type I IFN expres-
sion. Moreover, Trif also recruits TRAF6 and receptor-inter-
acting protein 1 (RIP1), with the help of TAK1, leading to
theactivationofNF-κBandMAPKsthroughubiquitination-
dependent mechanism similar to MyD88-dependent path-
way [2, 12].
Of note, TLR4 reportedly activates both MyD88- and
Trif-dependent pathways. After LPS binding, TLR4 initially
triggers MyD88-dependent pathway on the plasma mem-
brane and subsequently undergoes dynamin- and clathrin-
dependent endocytosis and translocates to the endosome
[2,62].Thistranslocation isnotonlyinvolvedindegradation
of TLR4, but also required for initiating Trif-dependent
pathway[2,62],whichleadstoIRF3activationaswell aslate-
phase activation of NF-κB[ 2, 62, 63].
3.TLRand Ischemic Myocardial Injury
TLRs are highly conserved and expressed ubiquitously
throughout species including mammals, chicken, ﬂies, and
plants. In mammals, they are expressed diﬀerentially in im-
mune cells such as monocytes/macrophage [64], neutrophil
[65, 66], natural killer cells [67], dentritic cells [68], mast
cells [69], speciﬁc T and B lymphocytes [70, 71], and non-
immune cells, such as epithelial cells [72], skin keratinocytes
[73], ﬁbroblasts [74], and cardiomyocytes and endothelial
cells in the heart [75–77]. Gene expression of TLR2, TLR3,International Journal of Inﬂammation 5
TLR4, TLR5, TLR7, and TLR9 has been reported in mouse
heart tissue and in cardiomyocyte cell line [75–77]. Signaling
via TLR2, TLR4, and TLR5, but not TLR3, TLR7, or TLR9,
can initiate proinﬂammatory cytokines expression and
inhibit cardiomyocyte contractility [75, 78]. Moreover, the
mRNA expression of all 10 TLRs has been identiﬁed in the
human heart tissue [79]. The one with highest expression is
TLR4, whereas the lowest ones are TLR8, TLR9, and TLR10.
While tissue hypoxia is the initial cause of myocardial
injury during transient ischemia, reperfusion-induced myo-
cardial inﬂammation is an important contributor to ische-
mia-induced myocardial injury [80]. In fact, innate immune
response is by far the most common cause of myocardial
inﬂammation after I/R, characterized as proinﬂammatory
cytokine release, endothelial cell activation, complement
deposition, inﬂammatory cell inﬁltration, and increased
vascular permeability [81–83]. Many of these inﬂammatory
responses are regulated by NF-κBsignaling pathway [84, 85].
Since TLRs are important upstream activators of NF-κBs i g -
naling, the role of TLRs in cardiac ischemic injury has been
intensely studied in the past 10 years [3]. Among those TLRs
expressed in the heart, TLR2 and TLR4 have been most
investigated (Table 2).
3.1. TLR2. Several studies have indicated that TLR2 signal-
ing is involved in myocardial I/R injury [86–89]. In an ex
vivo model of I/R, TLR2−/− mice exhibited improved LV
function compared to WT mice following I/R [86]. TLR2 is
alsoinvolvedin coronaryartery endothelialdysfunction with
impaired vessel relaxation induced by transient ischemia
[87]. Similar to TLR4-deﬁcient animals, TLR2−/− mice had
reduced inﬂammatory responses and smaller MI sizes after
I/R compared to WT control. Moreover, using chimeric
TLR2 deletion models, Arslan and coworkers demonstrated
that leukocyte TLR2 played a prominent role in mediating
myocardial injuryduringI/R.TheyfoundthatWT micewith
circulatory cells derived from TLR2−/− mice were protected
from I/R injury [88]. Administration of an anti-TLR2
antibody prior to reperfusion reduced MI sizes, preserved
cardiac function, and decreased scar formation. Importantly,
these cardiac beneﬁts in TLR2−/− mice were associated with
persistent attenuation of myocardial inﬂammation, such
as reduced leukocytes inﬁltration and attenuated proin-
ﬂammatory cytokines production. Interestingly, chemokines
and adhesion molecules, which are essential for recruiting
leukocytes to ischemic myocardium, were not changed.
3.2. TLR4. Several studies have demonstrated that TLR4
plays an important role in mediating immune cells inﬁltra-
tion, cytokine production, and complement activation dur-
ing I/R. Oyama and colleagues [90]ﬁ r s td e m o n s t r a t e dt h a t
aftertransient ischemia (1hofcoronary artery occlusionand
24hofreperfusion), TLR4-deﬁcientmice,C57/B10ScCrand
C3H/HeJ, had signiﬁcantly smaller MI sizes with more than
50% reduction compared to their respective control mice,
C57/BL10 ScSn and C3H/OuJ. C57/B10 ScCr mice have
natural TLR4 gene deﬁciency, whereas C3H/HeJ mice have
a spontaneous missense point mutation in the TIR domain.
Furthermore, the decreased myocardial infarction in TLR4-
deﬁcient mice was associated with attenuated myocardial
inﬂammation as evidenced by fewer neutrophil inﬁltration,
less lipid peroxides production, and less complement 3
deposition in the heart [90].
In a similar, but shorter, in vivo protocol (1h of ischemia
followed by 2h of reperfusion), Chong and colleagues [91]
independently demonstrated a cardiac protection in C3H/
HeJ mice with 40% reduction of MI compared to WT mice.
I/R induced signiﬁcant activation of ERK, p38 MAPK, and
JNK, and translocation of NF-κBa n dA P - 1i nW Tm i c e .
However, in C3H/HeJmice, there was a signiﬁcant reduction
in JNK and NF-κB/AP-1 activity and mRNA levels of myo-
cardial IL-1β,I L - 6 ,a n dM C P - 1[ 91]. Moreover, blunting
TLR4 signaling by eritoran, a speciﬁc TLR4 antagonist, also
resulted in decreased MI sizes and attenuated myocardial
inﬂammatory responses, such as reduced JNK phosphoryla-
tion, attenuated NF-κB nuclear translocation, and decreased
gene transcripts of TNFα,I L - 1 β, IL-6, MCP-1, MIP-1α,a n d
MIP-2 [92].
TLR4 may also mediate systemic cytokine production
following myocardial I/R injury. Kim and colleagues mea-
sured the protein level of proinﬂammatory cytokines in
t h em y o c a r d i u ma n ds e r u ma f t e rI / R[ 93]. They noticed a
robust increase in the serum levels of TNFα,I L - 1 β,a n dI L -
6 in response to 1h of ischemia and 2h of reperfusion in
vivo. TLR4 deletion led to signiﬁcant reduction in systemic
inﬂammation, but only selective reduction in myocardial IL-
6, and reduced MI sizes [93]. The authors thus speculat-
ed that systemic rather than local inﬂammatory response in-
volving TLR4 signaling contributes to I/R injury.
In an isolated heart model of global I/R, which is devoid
of circulating cells or other blood components, Cha and col-
leagues found that TLR4-deﬁcient hearts had reduced lev-
els of TNFα and IL-1β and improved cardiac contractile
function compared to WT hearts [94]. Administration of
TNFαandIL-1β toTLR4defectiveheart, however, abrogated
the beneﬁcial eﬀect of functional recovery in TLR4-deﬁcient
heartsafterglobalischemia[94],whereasfunctionalrecovery
after ischemia was also improved in TNFα-a n dI L - 1 β-def-
icient hearts, as well as in wild-type hearts treated with TNF-
binding protein or IL-1 receptor antagonist. These studies
suggest that myocardial TLR4 signaling may contribute to
cardiac dysfunction viaTNFα-a n dIL - 1β-dependent mecha-
nisms after global I/R [94]. Interestingly, in a similar ex vivo
model of I/R injury, Meng and colleagues found that 70-
kDa heat shock cognate protein was released from ischemic
myocardium and mediates, via a TLR4-dependent mecha-
nism, myocardial NF-κB activation and cytokine/chemokine
production in response to I/R [95, 96].
TLR4 signaling may also mediate inﬂammatory response
and contribute to myocardial injury during heart trans-
plantation. In a mouse model of heart transplantation,
Kaczorowski and colleagues [97, 101] demonstrated that the
serum myocardial injury marker, troponin I, was markedly
increased in the recipient mice. This was associated with
elevated serum inﬂammatory cytokines, such as TNFα,I L -
1β, IL-6, and MCP-1. Similarly, myocardial inﬂammation
was also dramatically induced in the graft. However, all6 International Journal of Inﬂammation
T
a
b
l
e
2
:
R
o
l
e
o
f
T
L
R
s
i
n
m
y
o
c
a
r
d
i
a
l
i
n
ﬂ
a
m
m
a
t
i
o
n
a
n
d
i
n
j
u
r
y
a
f
t
e
r
a
c
u
t
e
i
s
c
h
e
m
i
a
/
r
e
p
e
r
f
u
s
i
o
n
.
M
i
c
e
s
t
r
a
i
n
s
I
/
R
m
o
d
e
l
s
I
/
R
p
r
o
t
o
c
o
l
s
M
I
C
a
r
d
i
a
c
f
u
n
c
t
i
o
n
I
n
ﬂ
a
m
m
a
t
i
o
n
T
L
R
s
N
F
-
κ
B
a
c
t
i
v
i
t
y
C
y
t
o
k
i
n
e
p
r
o
d
u
c
t
i
o
n
M
y
o
c
a
r
d
i
a
l
n
e
u
t
r
o
p
h
i
l
i
n
ﬁ
l
t
r
a
t
i
o
n
E
C
d
y
s
f
u
n
c
-
t
i
o
n
/
R
O
S
↑
R
e
f
.
M
y
o
c
a
r
d
i
u
m
S
e
r
u
m
m
R
N
A
P
r
o
t
e
i
n
T
L
R
2
T
L
R
2
−
/
−
,
T
I
R
A
P
−
/
−
e
x
v
i
v
o
3
0
 
I
/
6
0
 
R
↑
T
N
F
α
,
I
L
-
1
β
[
8
6
]
T
L
R
2
−
/
−
i
n
v
i
v
o
3
0
 
I
/
1
h
R
↓
I
L
-
1
β
↓
↓
[
8
7
]
T
L
R
2
−
/
−
c
h
i
m
e
r
i
c
,
W
T
w
i
t
h
A
n
t
i
-
T
L
R
2
i
n
v
i
v
o
3
0
 
I
/
2
4
h
R
↓
↑
T
N
F
α
,
I
L
-
1
β
,
I
L
-
1
0
,
M
-
C
S
F
↓
[
8
8
]
T
L
R
2
−
/
−
,
W
T
w
i
t
h
A
n
t
i
-
T
L
R
2
i
n
v
i
v
o
2
0
 
I
/
2
4
h
R
↓
↓
[
8
9
]
T
L
R
4
C
5
7
B
L
/
1
0
S
c
C
r
C
3
H
/
H
e
J
i
n
v
i
v
o
6
0
 
I
/
2
4
h
R
↓
↓
[
9
0
]
C
3
H
/
H
e
J
i
n
v
i
v
o
6
0
 
I
/
2
h
R
↓
↓
T
N
F
α
,
I
L
-
1
β
,
M
C
P
-
1
,
I
L
-
6
[
9
1
]
W
T
w
i
t
h
E
r
i
t
o
r
a
n
i
n
v
i
v
o
3
0
 
I
/
2
h
R
↓
T
N
F
α
,
I
L
-
1
β
,
M
C
P
-
1
,
I
L
-
6
,
M
I
P
-
1
,
M
I
P
-
2
[
9
2
]
C
3
H
/
H
e
J
i
n
v
i
v
o
6
0
 
I
/
2
h
,
2
4
h
R
↓
N
S
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
[
9
3
]
C
5
7
B
L
/
1
0
S
c
C
r
C
3
H
/
H
e
J
e
x
v
i
v
o
2
0
 
I
/
6
0
 
R
↑
↓
T
N
F
α
,
I
L
-
1
β
[
9
4
]
W
T
w
i
t
h
A
n
t
i
-
H
S
C
7
0
e
x
v
i
v
o
2
0
 
I
/
6
0
 
R
↑
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
[
9
5
]
C
3
H
/
H
e
J
e
x
v
i
v
o
H
S
C
7
0
↑
↓
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
[
9
5
]
C
3
H
/
H
e
J
e
x
v
i
v
o
2
0
 
I
/
6
0
 
R
K
C
,
M
C
P
-
1
K
C
,
M
C
P
-
1
p
e
r
f
u
s
e
d
N
E
↓
[
9
6
]International Journal of Inﬂammation 7
T
a
b
l
e
2
:
C
o
n
t
i
n
u
e
d
.
M
i
c
e
s
t
r
a
i
n
s
I
/
R
m
o
d
e
l
s
I
/
R
p
r
o
t
o
c
o
l
s
M
I
C
a
r
d
i
a
c
f
u
n
c
t
i
o
n
I
n
ﬂ
a
m
m
a
t
i
o
n
T
L
R
s
N
F
-
κ
B
a
c
t
i
v
i
t
y
C
y
t
o
k
i
n
e
p
r
o
d
u
c
t
i
o
n
M
y
o
c
a
r
d
i
a
l
n
e
u
t
r
o
p
h
i
l
i
n
ﬁ
l
t
r
a
t
i
o
n
E
C
d
y
s
f
u
n
c
-
t
i
o
n
/
R
O
S
↑
R
e
f
.
M
y
o
c
a
r
d
i
u
m
S
e
r
u
m
m
R
N
A
P
r
o
t
e
i
n
C
3
H
/
H
e
J
i
n
v
i
v
o
t
r
a
n
s
p
l
a
n
t
a
t
i
o
n
2
h
I
/
3
h
,
2
4
h
R
↓
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
,
I
C
A
M
-
1
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
,
I
C
A
M
-
1
↓
[
9
7
]
M
y
D
8
8
W
T
w
i
t
h
A
d
-
d
n
M
y
D
8
8
i
n
v
i
v
o
4
5
 
I
/
4
h
R
↓
↓
[
9
8
]
M
y
D
8
8
−
/
−
i
n
v
i
v
o
3
0
 
I
/
2
4
h
R
↓
↑
M
C
P
-
1
,
K
C
,
I
C
A
M
-
1
↓
[
9
9
]
M
y
D
8
8
−
/
−
e
x
v
i
v
o
2
0
 
I
/
4
0
 
R
N
S
N
S
[
9
9
]
M
y
D
8
8
−
/
−
c
h
i
m
e
r
i
c
i
n
v
i
v
o
3
0
 
I
/
2
4
h
R
↓
N
S
↓
[
1
0
0
]
O
t
h
e
r
s
C
D
1
4
−
/
−
,
M
y
D
8
8
−
/
−
,
T
r
i
f
−
/
−
i
n
v
i
v
o
t
r
a
n
s
p
l
a
n
t
a
t
i
o
n
2
h
I
/
3
h
,
2
4
h
R
↓
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
,
I
C
A
M
-
1
T
N
F
α
,
I
L
-
1
β
,
I
L
-
6
,
I
C
A
M
-
1
↓
[
1
0
1
]
N
S
:
n
o
s
i
g
n
i
ﬁ
c
a
n
t
d
i
ﬀ
e
r
e
n
c
e
.8 International Journal of Inﬂammation
of these inﬂammatory responses were attenuated in TLR4-
deﬁcient mice subjected to the same transplantation proto-
col, suggesting that TLR4 signaling mediates myocardial
injuryandsystemicandlocalinﬂammation duringthetrans-
plantation.
3.3. MyD88. Given its critical role in TLR signaling, it is not
surprising thatMyD88alsoplaysa roleinmediating myocar-
dial innate immune response and contributes to injury after
I/R. Employing genetically modiﬁed mouse models or local
transgene expression of dominant negative MyD88 (dn-
MyD88), investigators demonstrate that MyD88 signaling
participates in I/R-induced myocardial inﬂammation and
myocardial infarction [98, 99]. In a rat model of I/R injury,
Hua and colleagues reported that adenoviral expression of
dn-MyD88 three days prior to the onset of myocardial
ischemia led to reduced infarct sizes and attenuated NF-κB
activity, consistent with the notion that MyD88 signaling
may contribute to ischemic myocardial injury by attenuating
inﬂammatory response that is dependent on NF-κBs i g n a l -
ing. One issue with adenovirus-mediated gene expression
in the myocardium, however, is the well-documented innate
immune response that may cause local inﬂammation rather
than attenuate it [102]. The challenge would be to separate
I/R-inducedinﬂammation fromadenovirus-mediated innate
immune response. In a mouse model of I/R injury, Feng and
colleagues found that compared to WT mice, mice deﬁcient
in MyD88 had markedly reduced myocardial infarction and
signiﬁcantly improved LV function between day 1 and day
7 after transient ischemia as measured by transthoracic
echocardiography [99]. MyD88−/− mice also exhibited sig-
niﬁcantly reduced myocardial cytokines and chemokines
[99, 100]. Flow cytometry analysis of cardiac cells isolated
from the digested hearts demonstrated a robust increase in
Gr-1+ neutrophils in the myocardium following I/R and
a very small number of neutrophils in the myocardium
of sham-operated mice. In contrast, there was a marked
reduction in myocardial Gr-1+ neutrophils in MyD88−/−
mice (Figure 2). Using an in vivo migration assay, the investi-
gators found that MyD88−/− mice had markedly attenuated
neutrophil migratory function, which was associated with
decreasedneutrophilCXCR2expression andlowertissueKC,
a neutrophil chemoattractant [100]. Interestingly, deletion
of Trif, another innate immune adaptor, had no impact on
myocardial neutrophil recruitment following I/R (Figure 2)
or on neutrophil CXCR2 modulation [100]. In an eﬀort to
determine the speciﬁc contribution of myocardial MyD88 to
cardiac injury following ischemia, Fengand colleaguestested
whether or not MyD88 deﬁciency would have any eﬀect
on myocardial injury in isolated mouse hearts. Surprisingly,
MyD88-deﬁciencyhad no signiﬁcant impact on MI sizes and
cardiac function in isolated hearts subjected to global I/R
[99]. This ﬁnding is consistent with the notion that the car-
diacbeneﬁtsobservedinMyD88−/− mice in vivo mayrequire
circulating blood components during I/R. Further studies in
chimeric MyD88 deletion models demonstrated that com-
pared to WT mice or WT mice transplanted with MyD88+/+
bone marrow (WT−→WT), WT mice transplanted with
MyD88−/− donor bone marrow (KO−→ WT) had signif-
icantly decreased MI sizes (Figure 3). Collectively, these
ﬁndings suggest that MyD88 signaling is essential for main-
tainingneutrophilmigratory function andchemokinerecep-
tor expression. MyD88 signaling in bone marrow-derived
neutrophils may play a speciﬁc and critical role in the devel-
opment of myocardial I/R-induced injury (Figure 4)[ 103].
4.TLRand Myocarditis
Myocarditis is deﬁned clinically as inﬂammation of the heart
muscle and has been identiﬁed as a major cause of sudden,
unexpected death in adults less than 40 years of age and
young athletes, accounting for approximately 20% of such
cases. It is estimated that the incidence of myocarditis in
the general population ranges from 1.06% to 5.0% [104–
106]. The causes of acute myocarditis include infection with
various pathogens (viral, bacterial, and fungi), autoimmune
disorders, systemic diseases, drugs, and toxins.
Viral Myocarditis. Viruses are the predominant cause of
myocarditis in North America and Europe, whereas Try-
panosoma cruzi and Chagas’ disease are the major contribu-
tors to the high incidence of myocarditis in South America.
While the exact role of various TLRs in the pathogenesis of
viral myocarditis and cardiomyopathy is yet to be deﬁned,
both protective and detrimental eﬀects have been reported
(Table 3).
4.1. TLR3. TLR3 recognizes dsRNA and is involved in
viral recognition. Hardarson and colleagues found that
compared toWT mice, TLR3-deﬁcient micewere susceptible
toencephalomyocarditisvirus(EMCV)infectionwithhigher
mortality, increased myocardial viral load, and more severe
myocardial injury [107]. Importantly, myocardial inﬂamma-
tory cell inﬁltration and cytokine mRNA expression, such
as TNFα,I L - 1 β,a n dI F N - β, were signiﬁcantly attenuated
and delayed in TLR3−/− mice. These data suggest that
EMCV infection induces a TLR3-dependent innate immune
response in the heart, which represents a critical host
protective mechanism against the virus-induced myocardial
injury and mortality.
A similar protective role of TLR3 was reported in CV-
induced myocarditis [108]. In that study, Negishi and col-
leagues demonstrated that compared to WT mice, TLR3−/−
mice had higher mortality, higher systemic and myocardial
v i r a lr e p l i c a t i o n ,a n dd e p r e s s e ds y s t e m i ca sw e l la sm y o c a r -
dial cytokine gene induction (IL-12p40 and IL-1β)a f t e rC V
infection. Local myocardial production of IFN-γ,n o tI F N -
β, was signiﬁcantly reduced in TLR3−/− hearts (Figure 5).
These studies demonstrate that type II IFN rather than type
I IFN plays a critical role in the antiviral responses of TLR3
signaling [108].
4.2. TLR4. TLR4 mRNA was reportedly increased in
endomyocardial biopsy samples from patients with clinically
suspectedmyocarditis andfromthosewithidiopathicdilated
cardiomyopathy. Immunohistochemical analysis revealed
that TLR4 was mainly expressed in inﬁltrated leukocytesInternational Journal of Inﬂammation 9
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Figure 2: Myocardial neutrophil recruitment after I/R in MyD88−/− and Trif−/− mice. Twenty-four hours after 60 min of left anterior
descending coronary artery (LAD) ligation, the hearts were isolated, perfused, and digested. After removal of the large cardiomyocytes
through ﬁltration, 50% of total cells were loaded onto ﬂow cytometry and gated on Gr-1 and CXCR2. (a) Total Gr-1+ cells as measured by
ﬂow cytometry from the hearts subjected to I/R in MyD88−/− mice. Each error bar represents mean ± SD of 4 mice. A small number of
neutrophils were recovered from the sham-operated hearts as indicated by the line. (b) A representative example of ﬂow cytometry plots
of myocardial inﬁltrating cells from sham, WT-I/R, and MyD88−/−-I/R mice. (c) Total Gr-1+ cells as measured by ﬂow cytometry from the
hearts subjected to I/R in Trif−/− mice. Each error bar represents mean ± SD of 3 mice. A small number of neutrophils were recovered from
the sham-operated hearts as indicated by the line. (d) A representative example of ﬂow cytometry plots of myocardial inﬁltrating cells from
WT-I/R and Trif−/−-I/R mice. FSC, forward scatter; SSC, side scatter. (Feng et al., [100], used with permission).10 International Journal of Inﬂammation
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Figure 3: Decreased MI sizes in MyD88-knockout (KO) and KO→WT chimeric mice compared with wild-type (WT) and WT→WT
chimeric mice. Mice were subjected to 30min of ischemia and 24h of reperfusion. At the end of reperfusion, animals were euthanized,
and area-at-risk (AAR) and MI were analyzed. (a) Representative of triphenyltetra zolium chloride (TTC) staining (bottom) and ﬂuorescent
microsphere distribution (top) of myocardial sections from the 4 groups of mice. The nonischemic area is indicated by red ﬂuorescent
staining,area at risk (AAR) by area devoid of red ﬂuorescent light, and infarct area by white. (b) Cumulative data of AAR/left ventricle (LV).
(c) Cumulative data of MI/AAR. Each error bar represents mean ± SD of 6–9 mice. (Feng et al.,[ 100], used with permission).
and cardiomyocytes. The increase in myocardial TLR4
mRNAexpressionwasassociatedwith enteroviralreplication
and cardiac dysfunction in human myocarditis [114]. In
an animal model of myocarditis, investigators found that
TLR4 and IL-12 receptor β1 exacerbated coxsackievirus
replicationandmyocarditis,whereas IFN-γ protectedagainst
viral replication [111]. TLR4 signaling was also associated
with increased proinﬂammatory cytokines (IL-1β and IL-
18) expression in the infected hearts, suggesting these two
cytokines play an important role in the pathogenesis of CV-
induced myocarditis [111].
4.3. MyD88 and Trif. As noted above, MyD88 and Trif are
two adaptors critical for TLR signaling, but their roles in the
pathogenesisofviralmyocarditisappearverymuchdiﬀerent.
F u s ea n dc o w o r k e r sf o u n dt h a tw i t h i nd a y sa f t e rC V B 3
inoculation, myocardial MyD88 and IRAK-4 expression was
elevated. Moreover, compared to WT mice, mice deﬁcient
in MyD88 had less myocardial inﬂammation and injury, re-
duced CVB3 viral titers, and improved survival [113]. The
myocardial cytokines (IL-1β,T N F α,I F N - γ, IL-10, and IL-
18) was signiﬁcantly decreased, but IFN-α and IFN-β were
increased in MyD88−/− mice. This study established MyD88
signaling as a major contributorto CVB-induced myocardial
inﬂammation and as a critical regulator in myocardial viral
replication possibly via type I IFN-dependent mechanism
[113]. On the other hand, Trif is the key adaptor essential for
TLR3 signaling. Similar to TLR3−/− mice subjected to viral
myocarditis, Trif−/− mice reportedly also had higher viral
load, attenuated cytokine gene expression than WT mice
[108, 112], and marked increase in mortality after CVB3 in-
fection [112]. The antiviral protection of Trif signaling was
probably mediated by type I IFN-β, since myocardial IFN-
β expression was markedly suppressed in Trif−/−mice and
administration of IFN-β eﬀectively reduced myocardial viral
load and local inﬂammation and markedly improved the
long-term survival rate in Trif-deﬁcient animals [112].12 International Journal of Inﬂammation
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Figure 4: Schematic diagram of cardiac infarct size (blue region) after acute ischemia and reperfusion (I/R) and neutrophil CXCR2 down-
regulation by deletion of myeloid diﬀerentiation factor 88 (MyD88) globally (right top) and targeted to leukocytes only (right bottom).
(Schmid-Sch¨ onbein, [103], used with permission).
Autoimmune Myocarditis. There is compelling evidence in a
signiﬁcant subset of patients with myocarditis and in several
animal models of experimental autoimmune myocarditis
(EAM) that host autoimmunity plays an important role
in the pathogenesis of myocarditis and subsequent dilated
cardiomyopathy [115]. TLR signaling activates the adaptive
immune system by inducing proinﬂammatory cytokine
production and upregulating costimulatory molecules of
antigen presenting cells and is involved in autoimmune
myocarditis.
In a mouse model of EAM, Nishikubo and colleagues
[116] demonstrated that TLR4-induced Th1 immune re-
sponse was required for the development of myocarditis in-
duced by myosin and BCG. Similarly, in comparison to WT
littermates,MyD88−/− micewere protectedfrom myocarditis
after immunization with α-myosin heavy chain-derived pep-
tide (MyHC-α) and complete Freund’s adjuvant [117]. This
protection against EAM is due to impaired expansion of
heart-speciﬁc CD4+ T cells after immunization. The serine/
threonine kinase PKC-θ is required for certain T cell-driven
autoimmune responses such as myocarditis. Mice deﬁcient
in PKC-θ did not develop EAM. However, TLR9 activation
by CpG could overcome the PKC-θ deﬁciency and restored
EAM in PKC-θ-deﬁcient mice by activation of T cells [118].
TodeterminetheroleoftheintracellularTLRsinEAM,Pagni
and colleagues induced experimental EAM in mice deﬁcient
in TLR3, TLR7, and TLR9 by immunization with MyHC-α
andcompleteFreund’sadjuvant.Theyfoundthatmyocardial
cellular inﬁltration and in vitro proliferation of MyHC-α-
restimulated splenocytes were markedly reduced in TLR7−/−
and MyD88−/− mice, while TLR3−/− and TLR9−/− mice
showed similar myocardial inﬂammatory cell inﬁltration as
WT mice. These data suggest that TLR7 and MyD88 signal-
ing mediates myocardial inﬂammation and injury during
the EAM [109]. Zhang and colleagues reported that human
cardiac myosin could act as an endogenous ligand to directly
activate human monocytes to release proinﬂammatory cy-
tokines. This eﬀect of human myosin is TLR2 and TLR8 de-
pendent [119].
5.TLRand SepticCardiomyopathy
Sepsis is deﬁned as the systemic inﬂammatory response syn-
drome thatoccursduring infection. It hasan estimated prev-
alence of 751,000 cases each year in the United States, and
over 210,000 of them die [120]. Sepsis is the 10th leadingInternational Journal of Inﬂammation 13
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cause of death in the US [121]. Cardiovascular collapse in-
duced by cardiac dysfunction and profound vasodilatation
represents a main feature of septic shock and contributes
to its high mortality. Since TLRs play an essential role
in recognizing various microbial components such as LPS,
lipoprotein, viral/bacterial DNA, these receptors play a piv-
otal role in the host innate immune defense and facilitate the
adaptive immunity against foreign pathogens. On the other
hand, inappropriate and imbalanced host immune response
via TLR-dependent mechanisms may also contribute to the
pathogenesis of sepsis.
5.1. TLR2. Knuefermann and colleagues [122]d e m o n -
strated that infusion of the Gram-positive bacteria S. aureus
to isolated perfused heart activated myocardial IRAK-1 and
NF-κBsignaling, increased TNFαand IL-1β production,and
induced marked contractile dysfunction under an ex vivo
condition. The cardiac eﬀects of S. aureus was dependent on
myocardialTLR2,sinceTLR2-deﬁcientheartswereprotected
from the above inﬂammatory responses and myocardial dys-
function. Zhu and colleagues [78] demonstrated that pep-
tidoglycan-associated lipoprotein, a naturally occurring
TLR2 agonist and a ubiquitous Gram-negative bacterial
outer-membrane protein that is shed by Gram-negative bac-
teria (e.g.,E. coli)into the circulationof septicanimals [123],
induced pro-inﬂammatory cytokine production and directly
inhibitedcardiomyocytefunction(sarcomereshorteningand
Ca2+ transients) in vitro. Zouand colleagues[124, 125]dem -
onstrate that TLR2 plays a critical role in myocardial inﬂam-
mation, ROS production, and cardiac dysfunction during
bacterial sepsis. In a mouse model of polymicrobial sepsis
(cecum ligation and puncture, (CLP)), these investigators
found that compared to WT mice, TLR2−/− mice had better
survival, markedly improved cardiac function as measured
by serial echocardiography, left ventricular pressure in iso-
lated heart, and sarcomere shortening/Ca2+ transients in iso-
lated cardiomyocytes (Figure 6), and depressed systemic and
myocardial inﬂammatory cytokines production [124]. They
further demonstrated that TLR2 activation by Pam3cys was
suﬃcient to induce intracellular ROS production in neu-
trophils and cultured cardiomyocytes in vitro and that TLR2
deﬁciency markedly reduced intracellular ROS production
in neutrophils isolated from polymicrobial peritoneal space
[125].Whileitremainsunclearwhetherornotpolymicrobial
sepsis exerts cardiac dysfunction directly through TLR2
signaling in vivo [126], recent evidence appears to suggest
that it is nonhematopoietic (parenchymal) TLR2 that plays
a predominant role in mediating myocardial inﬂammation
and cardiac dysfunction during polymicrobial sepsis [125]
and as noted above, pathogenic ligand activation of TLR2
caninducedirectfunctionaldepressionofisolatedcardiomy-
ocyte in vitro [78].
5.2. TLR4. The role of TLR4 in sepsis-induced cardiac dys-
function has been studied mainly in endotoxemic models.
LPS administration induces NF-κBa c t i v a t i o n[ 127]t h a t
leads to robust myocardial cytokines expression, such as
TNFα,I L - 1 β, and myocardial dysfunction [128, 129]. LPS
also reportedly upregulates TLR4 and CD14. Mice deﬁcient
in TLR4, CD14, and IRAK-1 were protected from endotoxic
shock with reduced myocardial inﬂammation and improved
cardiac function [129–131]. It is unclear, however, whether
or notLPSelicitsitscardiacdepressive eﬀectdirectlythrough
myocardial TLR4. A few studies suggest that LPS-induced
cardiac dysfunction may be an indirect eﬀect secondary to
immune cell TLR4 activation. For example, Tavener and col-
leagues [132] found that cardiomyocytes isolated from LPS-
treated mice exhibited reduced sarcomere shortening and
Ca2+ transients, whereas in vitro treatment with LPS failed to
inhibit cardiomyocyte function. Further studies in chimeric
mice suggest that TLR4 in bone marrow-derived hematopoi-
etic cells is probably responsible for cardiac dysfunction dur-
ing endotoxic shock [132–134]. However, using similar chi-
meric models, Fallach and colleagues recently found that,
micedeﬁcientinTLR4inbonemarrow-derived cells,butnot
in parenchymal tissues, remain to be sensitive to LPS chal-
lenge. They suggest that cardiomyocyte, not hematopoietic,
TLR4 contributes to cardiac depression during endotoxemia
[135].
It should be pointed out that while endotoxin models are
highly reproducible and can provide great insight into in-
ﬂammatory processes [136], these ligand-based models lack
an infectious focus and do not closely mimic the pathophys-
iology observed in septic patients. On the other hand, bacte-
rialinfectionmodelssuchasCLPcloselyresembletheclinical
scenario ofsepsissuch asbowel perforation. Importantly, the
contribution of TLR4 signaling in the two models of sepsis
may diﬀer signiﬁcantly. For example, studies have demon-
strated that TLR4 deletion confers a survival protection
against endotoxin shock [35, 137] but no survival beneﬁt in
CLP model [138]. These data suggest that host mobilizes dif-
ferent innate immune defense mechanisms in endotoxemia
and polymicrobial septic peritonitis [138]. Moreover, recent
data indicate that endotoxemia and CLP utilize diﬀerent sig-
naling pathways to induce cardiac dysfunction and systemic
inﬂammation. For example, MyD88, but not Trif, plays a
predominant role in mediating cardiac dysfunction, systemic
inﬂammation, and mortality during CLP, whereas MyD88
and Trif are both important for systemic inﬂammation, car-
diac depression and mortality during endotoxinshock[139].
These data clearly illustrate the critical diﬀerence in the role
of TLR4 signaling in these two models of sepsis.
5.3. TLR5. Rolli and coworkers ﬁrst demonstrated that bac-
terial ﬂagellin, a TLR5 ligand, induced marked myocardial
inﬂammation and contractile dysfunction [140]. In cultured
H9c2 cells and in primary rat ventricular cardiomyocytes,
ﬂagellin was found to activate NF-κB and MAPK and induce
TNFα and MIP-2 expression. The ﬂagellin-induced NF-κB
activation was TLR5-dependent. In vivo administration of
ﬂagellin led to myocardial NF-κB activation, and expression
of TNFα,I L - 1 β, IL-6, MIP-2, and MCP-1 increased myocar-
dial neutrophil inﬁltration, and reversible cardiac dysfunc-
tion [140]. However, it is yet to be determined if TLR5 sig-
naling plays a role in the pathogenesis of myocardial inﬂam-
mation and cardiac dysfunction in more clinically relevant
models of sepsis.International Journal of Inﬂammation 15
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5.4.TLR9. Paladuguandcolleagues[141]demonstratedthat
bacterialDNAand RNAderivedfromclinicallypathogenicS.
aureus and E. coli isolates induced a concentration-depend-
ent depression of maximum extent and peak velocity of con-
traction of rat ventricular cardiomyocytes. Signiﬁcant, but
more modest, depression was also induced by a nonpatho-
genic Escherichia coli isolate. Pretreatment with DNase or
RNase abrogated this eﬀect. Similarly, in vivo administration
of synthetic DNA (CpG-ODN) caused myocardial NF-κB
activation and inﬂammatory cytokine production (TNFα,
IL-1β,a n dI L - 6 ) .In vitro,C p G - O D Ni n h i b i t e ds a r c o m e r e
shortening of isolated mouse cardiomyocytes. Both the in
vivo and in vitro eﬀects of CpG were abolished in TLR9-
deﬁcient mice [142].
5.5. MyD88 and Trif. Using the CLP model [143]o ra
similar model [144], studies have established the critical role
of MyD88 signaling in the pathogenesis of polymicrobial
sepsis. In a colon ascendens stent peritonitis model, a highly
inﬂammatory model, MyD88−/− mice were found to be
protected with improved survival and attenuated systemic
inﬂammation within the ﬁrst 48 hours [144]. However, in
a CLP model with a low grade of severity of peritoneal
polymicrobial sepsis, MyD88−/− mice had worse survival
compared with WT mice despite signiﬁcantly attenuated
systemic inﬂammation and reducedlymphocyteapoptosisin
t h e s em i c e[ 143]. In comparison, the role of Trif signaling in
polymicrobial sepsis is not well understood. In a less severe
sepsis model, Trif-deﬁcient mice have reduced cytokine pro-
duction including TNFα, IL-6, and IL-10 suggesting Trif
signaling may contribute to systemic inﬂammation in a
mild form of animal sepsis [143]. Feng and colleagues
[139] compared the diﬀerent role of MyD88- and Trif-sig-
naling in endotoxemic and CLP models of sepsis. They
demonstrate that MyD88 signaling is the dominant deter-
minant in mediating inﬂammation, cardiac dysfunction, and
mortality, whereas Trif signaling plays no major role, in the
development of cardiac dysfunction and mortality in severe
polymicrobial sepsis. But, as noted above, in endotoxemic
model, MyD88 and Trif play an equally important role in
mediating inﬂammation (IL-1β,I L - 6 ,a n dT N F α), cardiac
depression, and high mortality [139].16 International Journal of Inﬂammation
6.Summaryand Perspective
During the past decade, studies characterizing the role of
TLRs in the innate immunity and the immunopathology of
humandiseaseshavebeenextensive.Awidevarietyofmicro-
bial and nonmicrobial TLR ligands have been identiﬁed.
These ligands act through their respective TLRs and elicit
a variety of biochemical and proinﬂammatory responses
via the distinct intracellular signal transduction systems. By
medicating the critical and complex tissue inﬂammatory
signaling, either protective or damaging in nature, TLRs play
a pivotal role in the pathogenesis of cardiac critical condi-
tions, such as acute ischemic myocardial injury, viral and
autoimmune myocarditis, and septic cardiomyopathy. Sev-
eral important future directions can be enumerated for char-
acterization of the cellular and molecular mechanisms by
which TLRs contribute to these cardiac conditions. While
numerous studies have indicated the possible contributory
role of TLRs in the development of ischemic myocardial
injury, there are many unanswered questions that are critical
for our ultimate understanding of the role of TLR signaling.
For example, what are the speciﬁc contributions of cardiac
versus immune cell TLRs to myocardial inﬂammation and
infarction following I/R? How does the dual role of TLR4
signaling, that is, proinﬂammatory versus antiapoptotic eﬀect,
determine the ﬁnal phenotypic outcome of myocardial inju-
ry [145]? How can we promote the protective precondition-
ing eﬀect and at the same time prohibits the injurious
proinﬂammatory eﬀect of TLR signaling during myocardial
ischemia [3]?Delineatingthesecellularandmoleculardetails
will help the future design of therapeutic strategy. Future
studies will also be needed to delineate the role of cardiac
versus systemic TLRs in the development of septic cardiac
dysfunction and to deﬁne the intracellular mechanisms
that control TLR-mediated deleterious cardiac dysfunction
during sepsis. Without doubt, as we are developing new
knowledgeontheﬁne structure ofthecellularand molecular
mechanisms involved in these cardiac diseases, we will have
better understanding on the essential role of TLRs in the
human diseases. Dissecting the complex cellular and molec-
ular pathways by which TLR signaling controls myocar-
dial inﬂammation and cardiomyocyte injury will shed light
on the mechanisms of these diseases and have signiﬁcant
clinical implications.
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